CHICAGO--(BUSINESS WIRE)--Celsis International plc, a Chicago-based life science products and services company, today announced that the US Food and Drug Administration (FDA) has accepted a Celsis Drug Master File (DMF) for Celsis AKuScreen™. This is the second Celsis DMF that has been accepted by the FDA in the last four months. The Celsis DMFs provide specific technical and regulatory information to the FDA which allows companies wanting to use the Celsis Rapid Detection system to obtain regulatory approvals more efficiently.
